Introduction {#sec1}
============

Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, was discovered to be considerably overexpressed on most prostate cancer (PCa) cells and to correlate with its expression level the more advanced the disease becomes.^[@ref1]−[@ref4]^ The exceptional target characteristics of PSMA enabled the development of radiolabeled PSMA inhibitors and antibodies for imaging and endoradiotherapy of PCa.^[@ref5]−[@ref11]^ Although \[^68^Ga\]PSMA-HBED-CC ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) is the most widely studied PSMA agent for clinical PCa-PET imaging, \[^177^Lu\]PSMA I&T and \[^177^Lu/^225^Ac\]PSMA-617 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) are currently used for endoradiotherapy of metastatic castration-resistant prostate cancer (mCRPC).^[@ref12]−[@ref15]^

![Structures of PSMA I&T (**1**), PSMA-617, and PSMA-HBED-CC.](ao-2018-00790r_0001){#fig1}

Radioligand therapy with \[^177^Lu\]PSMA I&T is well tolerated and has been demonstrated to be an efficient treatment option in advanced mCRPCa. No renal toxicity was observed, and only a few cases of heavily pretreated patients developed grade 3 or 4 hematological toxicity, thus confirming the safety of \[^177^Lu\]PSMA I&T.^[@ref13]^ Dosimetric studies revealed that tumor lesions received the highest radiation doses (3.3 mGy/MBq), followed by the parotid glands (1.3 mGy/MBq) and the kidneys (0.8 mGy/MBq), which shows the parotid glands and the kidneys to be dose limiting.^[@ref14]^ On the basis of the experience gained so far, patients have already been treated with up to 10 cycles of ^177^Lu-labeled PSMA inhibitors without significant side effects, which relativizes the focus on the kidney as a "dose-limiting organ." However, a reduction of unwanted tissue uptake is generally recommended during the drug development of radiolabeled tracers to reduce the possible adverse effects.

A well-established approach to reduce unwanted renal accumulation of peptidic tracers and to enhance their in vivo elimination is the introduction of carbohydrate moieties.^[@ref16]−[@ref19]^ Several investigations have shown that the conjugation of a carbohydrate can significantly alter the in vivo and in vitro parameter and thus, for instance, reduce the kidney uptake, reduce unspecific tissue binding, or improve the overall biodistribution profile of the radiolabeled ligand. Therefore, with the intention to develop a PSMA inhibitor with low kidney uptake, we used PSMA I&T as a starting point and introduced a free amine group within the suberic acid spacer for rapid derivatization. After the conjugation of three different thio-linked carbohydrate moieties (two monosaccharides: galactose, mannose; one diglycoside: cellobiose), we evaluated the novel carbohydrated compounds with respect to the most important parameters, such as affinity, internalization, and lipophilicity. Additionally, we investigated the effect of carbohydration on albumin binding. On the basis of the in vitro data, \[^68^Ga\]PSMA galactose was selected for a further comparative in vivo evaluation with \[^68^Ga\]PSMA I&T in CB-17 severe combined immunodeficiency (SCID) mice.

Results {#sec2}
=======

Synthesis {#sec2.1}
---------

The introduction of thioglycosides into the linker region was achieved using Fmoc-[l]{.smallcaps}-Asu(O*t*Bu)-OH as the starting point ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The protection of the free carboxylic group and the concomitant removal of the *t*Bu protecting group with trifluoroacetic acid yielded 90% of **4** after RP-HPLC purification. Coupling of **4** with the binding motif **1** and subsequent benzyl deprotection resulted in 92% yield of **7**. DOTAGA-(I-y)fk was synthesized as previously published and condensed with **7** to establish **9** without further purification.^[@ref20]^ After Fmoc and subsequent *t*Bu deprotection, **10** was obtained in 41% yield after RP-HPLC purification. Condensation of **10** with the PfpOH-activated thioglycosides **11**, **12**, and **13** facilitated the final carbohydrated derivatives **14**, **15**, and **16** in yields of 3 to 10% after deacetylation and purification via RP-HPLC.

![Synthesis of the carbohydrated PSMA inhibitors **14**, **15**, and **16**. (a) HOAt, HATU, DIPEA, benzyl alcohol, \[DMF\]; (b) 95% TFA, 5% DCM; (c) **1**, HOBt, TBTU, DIPEA, \[DMF\]; (d) Pd/C (10%), H~2~, \[EtOH\]; (e) DIC, PfpOH, pyridine, \[DMF\]; (f) **3**, DIPEA, \[DMF\]; (g) 20% piperidine in DMF, \[DMF\]; (h) TFA; (i) **11**, DIPEA, \[DMF\]; (j) **12**, DIPEA, \[DMF\]; (k) **13**, DIPEA, \[DMF\].](ao-2018-00790r_0002){#fig2}

Radiochemistry {#sec2.2}
--------------

### ^68^Ga Labeling {#sec2.2.1}

The synthesis of the ^68^Ga-labeled PSMA inhibitors (e.g., 5.0 nmol) was achieved within 15 min after the start of the radiosynthesis and resulted in specific activities ranging from 35 to 53 GBq/μmol after cartridge purification. The radiochemical purity for all compounds was ≥97%.

### ^177^Lu Labeling {#sec2.2.2}

With minor modifications to the previously published protocol, ^177^Lu labeling was accomplished with radiochemical purities ≥98% and specific activities ranging from 10 to 53 GBq/μmol.^[@ref21]^

### ^125^I Labeling {#sec2.2.3}

(\[^125^I\]I-BA)KuE, the reference ligand for all in vitro studies, was synthesized according to procedures mentioned in the literature.^[@ref20],[@ref22]−[@ref24]^ Destannylation of the precursor **17** was achieved with \[^125^I\]NaI and peracetic acid within 10 min at room temperature. Consecutive cartridge purification, *t*Bu deprotection with trifluoroacetic acid, and purification via RP-HPLC resulted in the final product (\[^125^I\]I-BA)KuE with a radiochemical purity ≥99% and a radiochemical yield of 41 ± 10%.

PSMA Affinity (IC~50~) {#sec2.3}
----------------------

Binding to PSMA was determined using LNCaP human prostate cancer cells in a competitive binding assay with the ^nat^Ga or ^nat^Lu analogs of **14**, **15**, and **16** and (\[^125^I\]I-BA)KuE (*c* = 0.2 nM) as the radioligand. For comparison, the IC~50~ values of PSMA I&T (**1**) were taken from a previous publication,^[@ref7]^ in which the same binding assay was performed. The results given in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} show that the affinities of the monosaccharide derivatives **14** and **15** were not significantly higher compared to that of the reference PSMA I&T (**1**). The introduction of the disaccharide cellobiose (**16**) lowered the affinity, also not significantly. The different stereochemistry of the carbohydrates used in **14** and **15** showed minimal effect on the binding affinity.

###### PSMA Binding Affinities (IC~50~), Internalization (%), Lipophilicity (log *P*), and HSA Binding of the Investigated Compounds[a](#t1fn1){ref-type="table-fn"}

  PSMA inhibitor                   IC~50~ \[nM\]          internalization \[%\]   log *P*          HSA \[%\]           
  -------------------------------- ---------------------- ----------------------- ---------------- ------------------- ----------
  \[^nat/68^Ga\]PSMA I&T           (^nat/68^Ga-**1**)     9.4 ± 2.9               59.2 ± 1.7       --4.31 ± 0.32       52.0
  \[^nat/177^Lu\]PSMA I&T          (^nat/177^Lu-**1**)    7.9 ± 2.4               75.5 ± 1.6       --4.12 ± 0.10       78.6
  \[^nat/68^Ga\]PSMA galactose     (^nat/68^Ga-**14**)    7.9 ± 3.9\*             18.7 ± 4.1\*\*   --4.15 ± 0.07\*     7.7\*\*
  \[^nat/177^Lu\]PSMA galactose    (^nat/177^Lu-**14**)   5.8 ± 0.6\*             60.2 ± 2.8\*\*   --3.95 ± 0.12\*     23.3\*\*
  \[^nat/68^Ga\]PSMA mannose       (^nat/68^Ga-**15**)    7.1 ± 0.3\*             8.4 ± 0.2\*\*    --4.01 ± 0.08\*     7.6\*\*
  \[^nat/177^Lu\]PSMA mannose      (^nat/177^Lu-**15**)   5.9 ± 0.5\*             35.3 ± 2.9\*\*   --3.85 ± 0.04\*\*   25.1\*\*
  \[^nat/68^Ga\]PSMA cellobiose    (^nat/68^Ga-**16**)    10.8 ± 1.7\*            4.0 ± 0.6\*\*                        6.9\*\*
  \[^nat/177^Lu\]PSMA cellobiose   (^nat/177^Lu-**16**)   12.5 ± 2.3\*            22.3 ± 1.2\*\*   --4.04 ± 0.10\*     19.9\*\*

Binding assays (IC~50~) were performed using LNCaP cells (150 000/well) and (\[^125^I\]I-BA)KuE (*c* = 0.2 nM) as the radioligand. Cells were incubated in HBSS (1% BSA) at 4 °C for 1 h. Internalization values were corrected for unspecific binding and normalized to the reference (\[^125^I\]I-BA)-KuE (*c* = 0.2 nM for ^68^Ga and 0.5 nM for ^177^Lu compounds; 37 °C, 1 h, 125 000 cells/well, PLL-coated plates). Data for binding (IC~50~) and internalization are expressed as mean ± SD (*n* = 3). Data are expressed as mean ± SD (*n* = 6) for log *P*. HSA binding (%) was determined via HPLC and nonlinear regression calibration using the *t*~R~ of the ^nat^Ga- and ^nat^Lu-labeled PSMA inhibitors.\* = *P* \> 0.05; \*\* = *P* \< 0.05.

Internalization {#sec2.4}
---------------

LNCaP cells were used to investigate the cell surface binding and internalization of the ^68^Ga- and ^177^Lu-labeled compounds **14**, **15**, and **16**. The cell surface-bound fraction after 60 min incubation ranged from 0.6 to 1.0%, whereas the internalized fraction displayed values from 1.3% for ^68^Ga-**16** to 11.3% for ^177^Lu-**14** for the total applied activity. Normalized to the uptake of (\[^125^I\]I-BA)KuE, the results in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} show that all carbohydrated compounds exhibited significantly lower values in comparison to **1** and the ^68^Ga-labeled compounds internalized less than the ^177^Lu-analogs. Differences in the stereochemistry of **14** and **15** resulted in slightly higher internalization of the galactose derivative.

Human Serum Albumin Binding {#sec2.5}
---------------------------

Albumin binding was determined using a human serum albumin (HSA) column connected to an HPLC system.^[@ref25],[@ref26]^ Column calibration was always performed prior to the analysis of the ^nat^Ga- and ^nat^Lu-labeled PSMA inhibitors and resulted in a coefficient of determination (*r*^2^) \> 92% in all experiments. The results given in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} display a range of HSA binding from 6.9% for ^nat^Ga-**15** to 78.6% for ^nat^Lu-**1**. Comparing **14** and **15**, stereochemistry had only a marginal influence on the albumin-binding values. Overall, carbohydration reduced the albumin binding in comparison to the reference ligand **1**.

Lipophilicity {#sec2.6}
-------------

For all compounds, the respective ^177^Lu-labeled analogs were more lipophilic than the ^68^Ga-labeled counterparts. The introduction of a sugar moiety altered hydrophilicity only to a negligible extent and not significant with ^68^Ga-**14** being the most hydrophilic carbohydrated PSMA inhibitor displaying a log *P* value of −4.15 ± 0.07. Data for ^68^Ga- and ^177^Lu-**1** were obtained from a previously published report and are added in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} for comparison.^[@ref27]^

Metabolic Stability {#sec2.7}
-------------------

The in vivo stability of \[^177^Lu\]PSMA galactose was investigated in a healthy mouse 60 min postinjection (p.i.). [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} shows the extracted samples from the urine, blood, and kidneys, which were analyzed using radio-HPLC. The extraction rate of ^177^Lu-**14** using 2-PMPA as a competitor was ≥31% per investigated tissue (≥0.5 MBq) and enabled sufficient signal intensity. ^177^Lu-**14** was found to be stable over 60 min in all analyzed fractions.

![Metabolite study of ^177^Lu-**14**. Radio-HPLC analyses of quality control (QC) and extracts from homogenized organs and body fluids from a male CB-17 SCID mouse (60 min p.i., 25 MBq ^177^Lu-**14**). Chromolith column, binary gradient, flow rate 3 mL/min, 3% MeCN to 95% MeCN in 6 min, 95% MeCN for 3 min.](ao-2018-00790r_0003){#fig3}

μPET Imaging and Biodistribution {#sec2.8}
--------------------------------

^68^Ga-**14** exhibited lower uptake in non-PSMA-expressing tissue but also reduced tumor accumulation compared to ^68^Ga-**1** (3.7 ± 0.5% ID/mL vs 5.8 ± 0.3% ID/mL; 85 min p.i.; [Figures [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). The specificity of the PSMA-mediated tissue uptake of ^68^Ga-**14** in the kidneys and the xenograft was confirmed by the coinjection of 2-PMPA (8 mg/kg), which reduced the uptake in these tissues to the background level.

![Maximum intensity projections (MIPs) of μPET scans in LNCaP xenograft-bearing mice. Dynamic MIP (summed up frames 1 to 1.5 h p.i.) of (A) 7.0 MBq ^68^Ga-**1** (PSMA I&T) and (B) 12 MBq ^68^Ga-**14** (0.15--0.20 nmol of peptide, respectively). (C) Static MIP (1 h p.i. for 15 min) of ^68^Ga-**14** + PMPA coinjection (8 mg/kg). Arrow indicates LNCaP tumor xenograft uptake in (A,B) or blockade of tumor uptake in (C).](ao-2018-00790r_0004){#fig4}

![Time--activity curves (logarithmic and linear plot) in % ID/mL. (A) ^68^Ga-**14** in selected organs. Comparison of ^68^Ga-**14** vs ^68^Ga-**1** (PSMA I&T) in (B) tumor, (C) kidney uptake, and (D) blood pool (heart) uptake. Data obtained from μPET imaging in LNCaP xenograft-bearing CB-17 SCID mice.](ao-2018-00790r_0005){#fig5}

The logarithmic plot of the time--activity curves (TACs) in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} shows a linear decrease of ^68^Ga-**14** from the heart and muscle tissue. Direct comparison of ^68^Ga-**1** and ^68^Ga-**14** in the linear TAC in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} illustrates the reduced tumor uptake of ^68^Ga-**14** compared to ^68^Ga-**1** (3.7 ± 0.5 vs 5.8 ± 0.3% ID/mL, ^68^Ga-**14** and ^68^Ga-**1**, 85 min p.i.). However, it also shows that ^68^Ga-**14** accumulates to a lower extent in the kidneys with an earlier onset of elimination (43.1 ± 2.2 vs 74.6 ± 3.6% ID/mL, ^68^Ga-**14** and ^68^Ga-**1**, 85 min p.i.).

Except for the blood value 1 h p.i., ^68^Ga-**14** showed decreased tissue uptake compared to ^68^Ga-**1** ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). Reduced accumulation of ^68^Ga-**14** was further seen in the spleen, kidneys, and tumor (3.86 ± 1.32 vs 4.37 ± 0.64% ID/g uptake in tumor, ^68^Ga-**14** and ^68^Ga-**1**, 1 h p.i.). Progressive clearance of ^68^Ga-**14** from the kidneys and other tissues was visible up to 3 h after injection, whereas tumor uptake remained constant (3.85 ± 0.54% ID/g, 3 h p.i.).

![Biodistribution data (in % ID/g). Biodistribution in healthy CB-17 SCID mice for ^68^Ga-**1** at 1 h p.i. and in LNCaP tumor-xenograft bearing CB-17 SCID mice for ^68^Ga-**14** at 1 and 3 h p.i. (*n* = 4). \* = *P* \< 0.05.](ao-2018-00790r_0006){#fig6}

A direct comparison of the tumor-to-tissue ratios of ^68^Ga-**1** and ^68^Ga-**14** at 1 h p.i. in [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} shows slightly increased ratios for the carbohydrated derivative ^68^Ga-**14** compared to ^68^Ga-**1**. The reduced kidney and tumor uptake of ^68^Ga-**14** resulted in similar tumor-to-kidney ratios for both tracers (0.07 vs 0.06, ^68^Ga-**14** and ^68^Ga-**1**, respectively).

![Tumor-to-tissue ratios of ^68^Ga-**1** and ^68^Ga-**14** in selected organs at 1 h p.i. \* = *P* \< 0.05.](ao-2018-00790r_0007){#fig7}

Discussion {#sec3}
==========

The recent development of PSMA ligands has resulted in highly specific radiolabeled agents for radioguided surgery, endoradiotherapy, and imaging of PCa.^[@ref6],[@ref7],[@ref27]−[@ref31]^ One of the widespread clinically used compounds is PSMA I&T, a ligand recently developed by our group.^[@ref32]^ Although no significant side effects have been observed so far, possible adverse reactions due to unwanted uptake of \[^177^Lu\]PSMA I&T (**1**) in the kidneys and salivary glands might impact the cumulative radioactivity dose, which can be administered for endoradiotherapy.^[@ref14]^

Several investigations by our group have demonstrated that carbohydration is a valuable tool to optimize the pharmacokinetics of compounds showing unfavorable in vivo distribution patterns.^[@ref17],[@ref19],[@ref33]−[@ref37]^ It was also shown that depending on the utilized sugar moiety, the adjustment of renal drug handling is feasible.^[@ref34],[@ref38],[@ref39]^ Therefore, in this study, we have aimed at developing carbohydrated PSMA inhibitors with preserved bioactivity to investigate the effect of carbohydration on the in vivo profile of the theranostic tracer PSMA I&T.

The conjugation of the thioglycosides of galactose and mannose to the suberic acid linker unit between the binding motif and the peptidic scaffold surprisingly resulted in slightly higher affinities than in the parent compound **1** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) and demonstrated the unexpected tolerability of PSMA I&T to incorporate bulky hydrophilic moieties in close proximity to the S1-binding pocket.

These results are, however, in contrast to a recently published report by Bouvet et al.^[@ref40]^ Their \[^18^F\]FDG-based PSMA ligand exhibited only moderate binding to PSMA, whereas every other compound, modified with an aromatic residue, was found to have a significantly higher affinity.^[@ref40]^ The hydrophobic pocket adjacent to the S1-binding site of PSMA, which is amenable for π-stacking and π-cationic interactions with hydrophobic motifs, explains this observation because no such interactions are possible with a carbohydrate, such as \[^18^F\]FDG.^[@ref41]^ Yet, PSMA I&T was developed with the intention to interact in a bidentate mode with the binding cavity of PSMA and the remote arene-binding site through the peptidic spacer and, therefore, probably compensates the potentially negative steric requirement of the sugar moieties. Moreover, the tunnel region of PSMA was reported to be partially tolerant toward structural modification,^[@ref42],[@ref43]^ which might explain the fact that even the disaccharide analog ^nat^Lu-**16** exhibited a reasonably high affinity (IC~50~ = 12.5 ± 2.3 nM).

Although lipophilicity was only negligibly affected and resulted in log *P* values ≤ −3.85 for all investigated compounds, carbohydration had a considerable and significant impact on tracer internalization. In concordance with previous reports,^[@ref7],[@ref20]^ the ^68^Ga-labeled compounds exhibited constantly lower intracellular activity than the respective ^177^Lu-labeled analogs, and notably, the lowest internalization efficiency of only 4.0 ± 0.6% \[relative to the reference (\[^125^I\]I-BA)KuE\] measured in this study was observed for ^68^Ga-**16**. This observation might be explained by either the hexa- or the heptadentate complexation of gallium and lutetium, respectively, and thus the resulting additional free carboxylic group in the case of gallium, which might impede the in vitro interactions, which are necessary for internalization. A detailed structure--activity relationship about the mechanism of internalization after ligand binding to PSMA has not been reported so far. However, the general mechanism has been shown to rely on endocytosis via clathrin-coated pits.^[@ref1],[@ref44],[@ref45]^ Our data suggest that sterically demanding carbohydrates at this conjugation side of the molecule affect the internalization process of PSMA and display a low tolerance for bulky hydrophilic moieties within the tunnel region. Further, an additionally negative charge in the chelator region reduces the internalization rate. These results are in agreement with the findings of Liu et al., who stated that the binding of the inhibitor induces a conformational change in PSMA, which either interferes with or contributes to the interaction of PSMA's cytoplasmatic tail with clathrin and the clathrin adaptor protein-2.^[@ref46]^

Analogous to the decreased internalization rate, binding to human albumin declined significantly. After carbohydration, the value of ^nat^Ga-**14** is more than six times lower compared to that of ^nat^Ga-**1** (7.7% vs 48.7%; 1 h), and the same effect was observed for every other tested carbohydrated derivative in this study ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). It is known that human albumin binds especially to molecules with lipophilic structures and negative charges in close proximity. It is therefore reasonable that the carbohydrates interfere with the interaction of albumin with the otherwise lipophilic suberic acid structure of the parent ligand PSMA I&T. Because of the positive results observed by Suzuki et al.^[@ref34]^ regarding the reduction of kidney uptake after conjugation to galactose, ligand **14** was used for further investigation.

Delayed plasma clearance is especially interesting for possible therapeutic applications. Increased tracer activity in the blood pool leads to higher tracer availability and thus increases the probability of the ligand to bind the target and to be potentially internalized. This can be achieved, for example, through the introduction of an albumin-binding tag, as demonstrated for radiolabeled folic acid compounds and recently for PSMA ligands.^[@ref47]−[@ref49]^ In contrast, low plasma protein binding might be beneficial in terms of the low background activity for PET imaging quality with earlier acquisition after intravenous injection and reduced radiation doses during endoradiotherapy because radiolabeled PSMA tracers are retained at the target side. A higher unbound fraction in the blood pool should result in a faster plasma clearance, if the renal clearance into the bladder is considered as the primary elimination process.^[@ref50],[@ref51]^ This situation was clearly demonstrated in the dynamic μPET imaging and, compared to \[^68^Ga\]PSMA I&T, reduced background activity and faster plasma clearance of ^68^Ga-**14** were visible ([Figures [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}).

Yet, in contrast to the dynamic PET study, the biodistribution study showed an elevated blood activity level for the carbohydrated compound ^68^Ga-**14** compared to ^68^Ga-**1**. A possible explanation, besides the limited number of PET studies, is the possible metabolite formation. Nevertheless, no substantial metabolite formation of ^177^Lu-**14** after 60 min p.i. was observed ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Hence, the elevated blood uptake of ^68^Ga-**14** has so far not been attributable to a specific effect but rather explainable through the reduced unspecific uptake in other tissue compartments, as shown in the biodistribution study. Except for the blood value at 1 h p.i. (1.53% ID/g vs 0.96% ID/g, ^68^Ga-**14** vs ^68^Ga-**1**, respectively), equal (bone, pancreas) or lower uptake in all other investigated tissues was visible for ^68^Ga-**14** compared to ^68^Ga-**1** ([Figures [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Yet, only the ligand uptake in the lung, spleen, and pancreas is significantly lower compared to the reference PSMA I&T (*P* \< 0.05). Taking the superior in vitro parameter of ^nat/177^Lu-**14** compared to the ^nat/68^Ga-labeled derivative into account, a biodistribution study with ^177^Lu-**14** should result in a higher tumor uptake because of the higher affinity and internalization. However, the increased plasma protein binding would also lead to a higher blood uptake and therefore probably level out the tumor-to-tissue ratios.

A similar observation regarding blood uptake was reported by Susaki et al.^[@ref39]^ All carbohydrated vasopressin derivatives in their study displayed a higher blood level in comparison to the non-carbohydrated compound. Likewise, they contributed this effect to decreased unspecific tissue uptake and thus the resulting elevated plasma levels. Suzuki et al. showed additionally that derivatization with galactose reduced binding to microsomal kidney and liver fractions.^[@ref34]^

Several groups emphasize the importance of the internalization to increase the tumor accumulation of PSMA ligands.^[@ref20],[@ref44],[@ref52],[@ref53]^ The lower internalization of ^68^Ga-**14**, therefore, probably caused the slightly reduced tumor uptake compared to ^68^Ga-**1** (3.85 ± 0.54 vs 4.37 ± 0.64% ID/g, 1 h p.i.). In this respect, reduction of the internalization upon carbohydration may be considered as a drawback, and other carbohydrate moieties should be evaluated to investigate if distinct glycosides or other positions within the molecule are able to increase the internalization while maintaining high affinity. However, recent reports about the superiority of radiolabeled somatostatin-2 (sst~2~) antagonists compared to sst~2~ agonists and other tracer groups have led to reconsideration of the importance of the parameter internalization.^[@ref54]−[@ref57]^ It is so far not clear if a "real" antagonistic PSMA inhibitor without internalization would perform similarly to the sst~2~ antagonists. Hence, further studies regarding the internalization mechanism of PSMA and its importance are needed.

Conclusions {#sec4}
===========

Carbohydration altered the in vitro properties of PSMA I&T, but without significant benefit in vivo. Although high affinity was maintained, the internalization rate and especially the HSA binding dropped considerably after the introduction of a carbohydrate moiety. The derivatives **14**, **15**, and **16** demonstrate the possibility to conjugate highly hydrophilic bulky carbohydrates to PSMA I&T-based structures and thus increase the repertoire of pharmacokinetic modifications for further development of PSMA ligands, especially for compounds suffering from high lipophilicity.

Materials and Methods {#sec5}
=====================

General {#sec5.1}
-------

The general information about the used materials, methods, and synthesis of the carbohydrated derivatives **14**--**16** and the nonradioactive Ga- and Lu-labeled references \[^nat^Ga/^nat^Lu\]**14**--**16** together with the synthesis of the precursor used for ^125^I labeling to obtain the radioligand (\[^125^I\]I-BA)KuE for the in vitro experiments is found in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf). All analytical data regarding ESI-MS and RP-HPLC for the synthesized compound **14**--**16** are also found in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf).

Radiolabeling {#sec5.2}
-------------

### ^68^Ga Labeling {#sec5.2.1}

For in vitro and in vivo studies, the ^68^Ga-labeled compounds were prepared using a fully automated system employing a ^68^Ge/^68^Ga generator (iThemba Labs, South Africa) connected to GallElut+ system (SCINTOMICS GmbH, Germany). The radiolabeling was already described in previous reports.^[@ref20],[@ref58],[@ref59]^ The experimental details are provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf).

### ^177^Lu Labeling {#sec5.2.2}

The ^177^Lu-labeled compounds were prepared as previously described with minor modifications and used without further purification.^[@ref21]^ In short, into a 500 μL reaction tube, NH~4~OAc buffer (10 μL, 1.0 M, pH = 5.9), 0.75--1.0 nmol tracer (7.5--10 μL, trace-pure water, Merck, Darmstadt, Germany), and 10 to 40 MBq ^177^LuCl~3~ were added (specific activity (*A*~S~) \> 3000 GBq/mg, 740 MBq/mL, 0.04 M HCl, ITG, Garching, Germany), and the reaction mixture was filled up to 100 μL with trace-pure water. The reaction mixture was heated for 30 min at 95 °C and the radiochemical purity was determined using radio-TLC.

### ^125^I Labeling {#sec5.2.3}

The radioiodinated reference ligand (\[^125^I\]I-BA)KuE was synthesized in accordance with a previously published method and fully described in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf).^[@ref20]^

In Vitro Assays {#sec5.3}
---------------

### Cell Culture {#sec5.3.1}

PSMA-positive LNCAP cells (CLS: 300265; Cell Lines Service GmbH) were cultivated in Dulbecco modified Eagle medium/nutrition mixture F-12 (1:1) (DMEM-F12, Biochrom) supplemented with 10% fetal calf serum (Biochrom) and kept at 37 °C in a humidified 5% CO~2~ atmosphere. One day (24 ± 2 h) prior to all in vitro experiments with LNCaP cells, the cultivated cells were harvested using a mixture of trypsin/ethylendiaminetetraacetate (0.05%/0.02%) in phosphate-buffered saline (PBS) and centrifuged. After centrifugation, the supernatant was disposed and the cell pellet was resuspended in culture medium. Afterward, cells were counted with a hemocytometer (Neubauer) and seeded in 24-well plates. IC~50~ values were determined by transferring 150 000 cells/mL per well into 24-well plates, whereas internalization was assessed by transferring 125 000 cells/mL into 24-well PLL-coated plates.

### Determination of IC~50~ and Internalization {#sec5.3.2}

Detailed information regarding affinity and internalization experiments is provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf).^[@ref20]^

### Summary {#sec5.3.3}

The determination of binding affinity (IC~50~) was performed using LNCaP cells at 4 °C with (\[^125^I\]I-BA)KuE as the radioligand and the respective ^nat^Ga- and ^nat^Lu-PSMA inhibitors. After incubation for 1 h, the cell-bound and free activity were separated and quantified in a γ-counter. All experiments were performed in triplicate.

For internalization experiments, the ^68^Ga- and ^177^Lu-labeled compounds were incubated for 1 h at 37 °C. Afterward, the experiments were stopped through placing the 24-well plate on ice for 5 min. After separation of the supernatant (unbound fraction), the cell-surface-bound activity was removed through incubation with a 2-PMPA solution for 5 min. Finally, the internalized activity was gained through lysis with 1.0 M NaOH solution. All fractions were collected and quantified in a γ-counter, and the uptake was calculated relative to the uptake of (\[^125^I\]I-BA)KuE as the reference. All experiments were performed in triplicate.

### HSA Binding {#sec5.3.4}

HSA binding experiments were performed, as previously described, by the application of an HSA column connected to an HPLC system with a UV--vis detector.^[@ref25]^ The mobile phase consisted of a binary gradient system with a constant flow rate of 0.5 mL/min. Mobile phase A consisted of an ammonium acetate solution (50 mM, pH 6.9); mobile phase B was 2-propanol (HPLC grade, VWR, Germany). The gradient of mobile phase A was 100% from 0 to 3 min and from 3 min to the end of each run; mobile phase B was set at 20%. On each experimental day, the column was calibrated with nine reference substances to confirm the performance and to conduct the nonlinear regression. Afterward, the PSMA inhibitors with unknown HSA binding were measured. All substances were dissolved in a 0.5 mg/mL concentration and 5--10 μL was injected for each run. Further information is provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf).

### Lipophilicity {#sec5.3.5}

The log *P* values were determined, as previously described, using the shake flask method.^[@ref20]^

Statistical analysis was performed for affinity, internalization, and lipophilicity using a *t*-test (Microsoft Excel software). All analyses were two-tailed and considered as type 3 (two-sample unequal variance). A *P* value of less than 0.05 was considered statistically significant.

In Vivo Experiments {#sec5.4}
-------------------

All animal experiments were carried out in accordance with the general animal welfare regulations in Germany (Deutsches Tierschutzgesetz, approval \#55.2-1-54-2532-71-13). For the xenograft tumor model, LNCaP cells (approximately 10^7^ cells) were suspended in a serum-free DMEM-F12 medium and Matrigel (BD Biosciences, Germany) (1:1) and inoculated onto the right shoulder of 6 to 8 weeks old male CB-17 SCID mice (Charles River Laboratories, Sulzfeld, Germany). Animals were used for in vivo studies after the tumor size reached 4--8 mm in diameter.

### Metabolic Stability {#sec5.4.1}

\[^177^Lu\]PSMA galactose (^177^Lu-**14**; 25 MBq) was injected into the tail vein of a healthy CB-17 SCID mouse (*n* = 1), which was sacrificed after 60 min. Samples of the urine and blood were immediately taken. Kidneys were frozen with liquid nitrogen, homogenized, and extracted with 2-PMPA solution (500 μL, 400 μM in PBS). After centrifugation at 15 000*g* for 5 min, the suspension was ultrafiltrated and analyzed by radio-HPLC. The blood sample was centrifuged at 6000*g* for 5 min to obtain the plasma. To remove the proteins from the plasma, ice-cold MeCN was added to the sample, which was later incubated for 10 min at 4 °C. After concomitant centrifugation and ultrafiltration, the sample was analyzed by radio-HPLC. The urine sample was used without any further preparation.

### μPET Imaging {#sec5.4.2}

Imaging experiments were conducted using a Siemens Inveon small-animal PET. The resulting data were analyzed by the associated Inveon Research Workplace software. Mice were anaesthetized with isoflurane, and the compounds \[^68^Ga\]PSMA I&T (^68^Ga-**1**) and \[^68^Ga\]PSMA galactose (^68^Ga-**14**) (0.2 nmol, 7.0 and 12 MBq, respectively) were injected via the tail vein (*n* = 1). Dynamic imaging was carried out after on-bed injection for 90 min. The static blockade image was obtained after 1 h p.i. with 15 min acquisition time. Blockade was performed by coinjection of 8 mg/kg of 2-PMPA. All images were reconstructed using an OSEM 3D algorithm without scanner and attenuation correction.

### Biodistribution {#sec5.4.3}

Approximately 10.0 to 11.0 MBq (ca. 0.2 nmol) of \[^68^Ga\]PSMA galactose (^68^Ga-**14**) and 6.3--7.0 MBq (ca. 0.2 nmol) of \[^68^Ga\]PSMA I&T (^68^Ga-**1**) were injected into the tail vein of LNCaP tumor-bearing male CB-17 SCID mice (*n* = 4), which were sacrificed after either 1 h p.i. (^68^Ga-**1** and ^68^Ga-**14**) or 3 h p.i. (^68^Ga-**14**). Selected organs were removed, weighted, and measured in a γ-counter. Statistical analysis for the biodistribution study was performed using a *t*-test (Microsoft Excel software). All analyses were two-tailed and considered as type 3 (two-sample unequal variance). A *P* value of less than 0.05 was considered statistically significant.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00790](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00790).Additional details on experimental methods, synthesis, radiolabeling methods, and in vitro experiments ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00790/suppl_file/ao8b00790_si_001.pdf))
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PSMA

:   prostate-specific membrane antigen

μPET

:   micro-positron emission tomography

HSA

:   human serum albumin

mCRPC

:   metastasized castration-resistant prostate cancer

SCID

:   severe combined immunodeficiency

MIP

:   maximum intensity projection

TAC

:   time--activity curves

sst~2~

:   somatostatin-2

PBS

:   phosphate buffered saline

HOAt

:   1-hydroxy-7-azabenzotriazol

HATU

:   1-\[bis(dimethylamino)methylene\]-1*H*-1,2,3-triazolo\[4,5-*b*\]pyridinium 3-oxid hexafluoro-phosphate

DIPEA

:   *N*,*N*-diisopropylethylamine

DMF

:   dimethylformamide

DCM

:   dichloromethane

HOBt

:   *N*-hydroxybenzotriazole

TBTU

:   *N*,*N*,*N*′,*N*′-tetramethyl-*O*-(benzotriazol-1-yl)uronium tetrafluoroborate

Pd/C

:   palladium on activated charcoal

DIC

:   *N*,*N*′-diisopropylcarbodiimide

PfpOH

:   pentafluorophenol

*t*Bu

:   *tert*-butyl

Fmoc

:   9-fluorenylmethoxycarbonyl

2-PMPA

:   2-phosphonomethyl pentanedioic acid
